Vaxart Stock Soars 60.31% Ahead of Norovirus Vaccine Data

On June 11, 2025, Vaxart's stock surged by 60.31% in pre-market trading, marking a significant rise that has captured the attention of investors and analysts alike.

Vaxart, a clinical-stage biotechnology company, is set to release topline data from its Phase I norovirus vaccine trial on June 11, 2025. This announcement comes as part of the company's ongoing efforts to develop innovative oral recombinant pill vaccines. The data release is expected to provide insights into the progress and efficacy of Vaxart's norovirus vaccine, which is designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries.

In addition to the data release, Vaxart will host a conference call on the same day at 8:30 a.m. Eastern Time. The call will be led by the company's senior management team, who will discuss the trial results and provide updates on the development of Vaxart's vaccine programs. Investors and stakeholders are encouraged to participate in the call, which can be accessed via a webcast or by phone, and to submit questions in advance.

Vaxart's focus on developing oral vaccines positions the company as a pioneer in the biotechnology industry. The proprietary delivery platform used by Vaxart aims to provide non-refrigerated vaccine options, which could revolutionize the way vaccines are stored and administered. The company's development programs include vaccines for norovirus, coronavirus, influenza, and HPV, highlighting its commitment to addressing a range of infectious diseases and health conditions.